Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 8/20 | 0.64 |
| ▸ | PRMT6 | Q96LA8 | 8/20 | 0.64 |
| ▸ | MMP2 | P08253 | 1/20 | 0.50 |
| ▸ | MMP13 | P45452 | 1/20 | 0.50 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.49 |
| ▸ | BCHE | P06276 | 4/20 | 0.48 |
| ▸ | SLC6A5 | Q9Y345 | 5/20 | 0.47 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12041767 | 0.99 | CARM1 (0.65) | CARM1PRMT6MMP2MMP13LIPG | |
| Lithium Ion SCHEMBL381730 | 0.87 | CARM1 (0.63) | CARM1PRMT6MMP2MMP13LIPG | |
| SCHEMBL12041768 | 0.86 | CARM1 (0.68) | CARM1PRMT6MMP2MMP13BCHE | |
| SCHEMBL27629882 | 0.81 | CARM1 (0.57) | CARM1PRMT6MMP2MMP13LIPG | |
| SCHEMBL382502 | 0.79 | S1PR1 (0.53) | SIGMAR1 | |
| SCHEMBL12049739 | 0.78 | CARM1 (0.70) | CARM1PRMT6MMP2MMP13LIPG | |
| SCHEMBL12041500 | 0.77 | S1PR1 (0.54) | SIGMAR1 | |
| SCHEMBL19090879 | 0.76 | CARM1 (0.86) | CARM1PRMT6SLC6A5TMEM97SIGMAR1 | |
| SCHEMBL31381237 | 0.76 | CARM1 (0.50) | CARM1PRMT6MMP2MMP13LIPG | |
| SCHEMBL27399262 | 0.76 | TEAD1 (0.65) | CARM1PRMT6MMP2MMP13LIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096524-B2 | Anthelmintic agents and their use | INTERVET INTERNATIONAL B.V. (NL) | 2015-08-04 | — | — | US | disclosed |
| EP-2408742-B1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INT BV (NL) | 2014-09-03 | — | — | EP | disclosed |
| EP-2408742-A1 | ANTHELMINTIC AGENTS AND THEIR USE | Intervet International B.V. (NL) | 2012-01-25 | — | — | EP | disclosed |
| US-20110319393-A1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INTERNATIONAL B.V. (NL) | 2011-12-29 | — | — | US | disclosed |
| WO-2010115688-A1 | ANTHELMINTIC AGENTS AND THEIR USE | INTERVET INTERNATIONAL B.V. (NL) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319393-A1 | ANTHELMINTIC AGENTS AND THEIR USE | ACHE, ABCB11, MPO | CARM1 3331/4885PRMT6 3189/4885MMP2 1733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.